

Role of IL-6 and Insulin Resistance in the Etiopathogenesis of Atherosclerosis

Arpita Suri^{1*}, Ritu Singh², Sanjay Tyagi³, Jayashree Bhattacharjee²

^{1*}Assistant Professor, Department of Biochemistry, SGT Medical College, Hospital and Research Institute, Gurugram, Haryana, India.

[Ex PG Resident, Department of Biochemistry, Lady Hardinge Medical College, New Delhi, India]

²Director Professor, Department of Biochemistry, Lady Hardinge Medical College, New Delhi, India.

³Director Professor and HOD, Department of Cardiology, GB Pant Hospital, New Delhi, India.

ABSTRACT

Objectives: Our study attempts to evaluate the role of Nuclear Factor-kappa Beta (NF- κ B), Interleukin-6 and Homeostatic model assessment of insulin resistance (HOMA-IR) in assessment of severity of atherosclerosis currently assessed by angiography.

Methods: 50 cases of angiographically significant atherosclerosis (>50% obstruction in coronary arteries) and 50 age, sex, BMI matched patients with insignificant atherosclerosis (<50% obstruction) on angiography were selected from G.B Pant Hospital. Serum IL-6, NF- κ B was estimated by ELISA and serum insulin was estimated by CLIA.

Results: Serum IL-6, NF- κ B, Insulin and HOMA-IR were significantly raised in cases ($p=0.003, 0.05, 0.003, 0.012$ respectively). Upon correlation analysis, we observed that IL-6 has statistically significant correlation (Pearson's coefficient, $r=0.196$ and $p=0.04$) with NF- κ B. Upon binomial logistic regression analysis, NF- κ B emerged as the best predictor of severity of atherosclerosis (OD=19.2).

Conclusion: Our study shows that atherosclerotic progression is associated with inflammation, insulin sensitivity and endothelial dysfunction. The study also asserts a significant

correlation between inflammation and NF- κ B, thereby throwing light on critical role of NF- κ B in pathways of inflammation promoting atherosclerosis. Further studies in larger sample size are required to assess NF- κ B as marker of severity of atherosclerosis.

Keywords: Inteleukin-6, NF- κ B, Insulin Resistance, Atherosclerosis.


*Correspondence to:

Dr. Arpita Suri,
Assistant Professor,
Department of Biochemistry,
SGT Medical College, Gurugram, Haryana, India.

Article History:

Received: 09-05-2018, **Revised:** 02-06-2018, **Accepted:** 29-06-2018

Access this article online

Website: www.ijmrp.com	Quick Response code 
DOI: 10.21276/ijmrp.2018.4.4.010	

INTRODUCTION

IHD is the generic designation for a group of closely related syndromes resulting from myocardial ischemia--an imbalance between the supply (supply ischemia or low-flow ischemia) and demand of the heart for oxygenated blood (demand ischemia or high-flow ischemia). It is most commonly observed that myocardial ischemia is caused by atherosclerosis of the coronary arteries.¹

Most of the developing countries have witnessed a dramatic increase in the prevalence of IHD.² Cardiovascular diseases have assumed epidemic proportions in India as the estimated burden of Coronary Heart Disease is more than 32 million patients.³ According to the estimates from the GBD Study, by 2020 85% of the global cardiovascular disease burden is expected to be borne by developing nations out of which India is predicted to bear the greatest IHD burden.

Over the past few decades, the management of atherosclerosis mainly has been reduction of Low Density Lipoprotein (LDL)-

cholesterol by HMG-CoA synthetase inhibitors like statins. But in spite of success in lowering LDL, the epidemic of IHD continued to surge. Therefore, the focus of research has been shifted from dyslipidemia to inflammatory processes. Studies show inflammatory processes might have a key role in the initiation and progression of atherosclerosis.

Inflammatory processes have a key role not only in the initiation and progression of atherosclerosis but also in the stability of the established atherosclerotic plaques.⁴ Risk factors for cardiovascular disease like Diabetes Mellitus, smoking trigger a chronic inflammatory process, which leads to loss of vasodilatory and antithrombotic properties of the vascular endothelium (Endothelial dysfunction).⁵

The interplay between inflammatory processes and hormonal effects of insulin is emerging as key factors in etiopathogenesis. The inflammatory processes are mediated by cytokines like IL-6.

Interleukin (IL)-6 is a pleiotropic cytokine with a broad range of humoral and cellular immune effects relating to inflammation, host defense, and tissue injury.⁶

In a prospective study in apparently healthy men, Ridker et al⁷ proposed that elevated levels of IL-6 were associated with increased risk of future myocardial infarction.

Various studies suggests that Insulin resistance (IR) contributes to atherosclerosis and is an important factor in its pathogenesis. It is postulated that impaired insulin sensitivity results in atherosclerosis by various mechanisms. They include the anti-aggregating platelet effect of insulin⁸, the effect of the hormone on nitric oxide release from the endothelium⁹, the inhibition of migration of vascular smooth muscle cells¹⁰, and the inhibitory effect on fibrinogen synthesis¹¹ which are impaired in insulin-resistance.

Rel or NF-kappaB (NF-kB) proteins comprise a family of structurally-related eukaryotic transcription factors that are involved in the control of normal cellular processes such as immune and inflammatory responses by increasing the expression of specific cellular genes. These include genes encoding cytokines, receptors involved in immune recognition such proteins involved in antigen presentation and receptors required for neutrophil adhesion and migration.¹² NF-kB regulation of genes involved in the inflammatory response and cellular proliferation likely plays an important role in the initiation and progression of atherosclerosis.

Therefore, we studied IL-6, NF-kB and HOMA-IR (marker of insulin resistance) in patients with clinically significant atherosclerosis to understand further the etiopathogenesis of atherosclerosis and whether any of these can be used as biomarker to predict the severity of atherosclerosis.

MATERIALS AND METHODS

It was Descriptive Observational case control study conducted in the Department of Biochemistry in Lady Hardinge Medical College in collaboration with the Department of Cardiology, GB Pant Hospital after approval by the ethical committee of LHMC, New Delhi.

We enrolled 50 non diabetic cases diagnosed with angiographically significant atherosclerosis (>50% obstruction in coronary artery) and 50 age and sex matched controls with insignificant atherosclerosis (<50% obstruction) on angiography

after informed written consent. The patients on statins were excluded from the cases. The study was approved by institutional ethical committee of LHMC.

Venous blood sample was collected from the subjects under sterile condition after overnight fasting of 8-12 hrs. The sample was processed immediately for the routine biochemical investigations, hemogram and lipid profile. For special investigations, the plasma samples were stored at -20°C till subsequent analysis.

Special investigation like IL-6 was estimated by ELISA using kit from Diaclone Research (France) while NF-kB was estimated using a kit from Biomedical Medical assay (Beijing, China). Insulin level was estimated by chemiluminescence based immunoassay (CLIA) from Beckman Coulter (United States) and HOMA-IR was calculated for estimating insulin resistance. According to Homeostasis model assessment score of insulin resistance (HOMA-IR), IR= fasting serum insulin (µIU/ml) × fasting plasma glucose (mg/ml)/405.

Statistical Analysis

It was done by using SPSS (statistical package for social sciences) 20 version. All the data was expressed as mean ±SE of mean. The p value of < 0.001 was considered highly significant. The data obtained was compared between two groups by student t-test. Pearson’s correlation coefficient was applied for correlation between two quantitative variables. Binomial logistic regression was applied to obtain the best predictor of Atherosclerosis.

RESULTS

In the present study, we observed significantly (p=0.003) higher levels of IL-6 in study population (33.19±5.77 pg/ml) when compared to control (13.73±2.65 pg/ml) (figure 1) (table 1).In addition the mean serum NF-kB levels were also significantly (p=0.03) higher in the study group (0.33±0.10 ng/dl) as compared to control group (0.29±0.11 ng/dl) (figure 2) (table 1).Upon correlation analysis, we observed that IL-6 has statistically significant correlation (Pearson’s coefficient, r=0.296 and p=0.05) with NF-kB (figure 3).The mean serum insulin level raised significantly (p=0.003) in study group as compared to controls (9.96±5.25 vs 6.85±4.9 µIU/ml) (table 1).The mean serum HOMA-IR level in the study group (cases) was 2.95 ±0.26 and in the control group was 1.95±0.29 . The difference between the two was significant (p=0.012) (table1).

Table 1: Parameters in Study Population

Parameter	Study Group	Mean	S.E.M	P Value
IL-6	Case (n=50)	33.188	5.77	
	Control (n=50)	13.732	2.65	0.003*
Insulin	Case	9.96	0.74	0.003*
	Control	6.85	0.69	
HOMA-IR	Case	2.95	0.26	0.012*
	Control	1.95	0.29	
NF-kB	Case	0.33	0.014	0.050*
	Control	0.29	0.015	

*p value≤0.05 is considered statistically significant




Figure 1: Serum IL-6 Level in Study and Control Group




Figure 2: Serum Insulin Levels in Cases and Control Group




Figure 3: HOMA-IR Levels in Cases and Control Group




Figure 4: Serum NF-κB Levels in Cases and Control Group




Figure 5: Correlation Between IL-6 and NF-κB

DISCUSSION

In our study we found increase in pro-inflammatory marker (IL-6), NF-κB, markers of insulin resistance (HOMA-IR and serum insulin) in cases of significant atherosclerosis as compared to controls. The inflammatory marker, IL-6 level in the study group

(cases) was significantly higher as compared to controls. My findings are substantiated by different studies that confirm a close relationship between inflammation and atherosclerosis in an independent way. Ridker et al⁷ found an independent correlation

between IL-6 levels and coronary risk in healthy men. Yudkin et al¹³ also reported that IL-6 might play a key role in the development of coronary disease through a number of metabolic and endothelial mechanisms.

In 2003, Fernandez-Real et al¹⁴ also confirmed plasma concentrations of proinflammatory cytokines like IL-6 are increased in patients with ischemic heart disease. This can be attributed to the reversible ischemia which triggers an initial rapid release of preformed IL-6 from circulating monocytes, or cardiac mast cells, followed by enhanced production of IL-6.¹⁵ These findings emphasize the role of IL-6 as a potential marker of inflammation in diagnosis of ischaemic heart disease.

The mean serum NF- κ B level in the study group (cases) was 0.33 ± 0.10 and in the control group was $0.29 \pm 0.11 \mu\text{M}$ which was statistically significant ($p=0.05$). Worldwide there are very few clinical studies evaluating the role of NF- κ B in ischaemic heart disease. In 2001, Tak et al¹⁶ proposed that transcription factor nuclear factor- κ B (NF- κ B) is a key regulator of inflammation and plays a key role in various inflammatory diseases. In 2004 Jian Jun et al¹⁷ studied NF- κ B levels in Chinese patients with stable angina. He postulated that NF- κ B were raised in cases as compared to controls ($p<0.01$). In support of this Gerondakis S et al¹⁸ proposed that NF- κ B regulates host inflammatory and immune responses and cellular growth properties by increasing the expression of specific cellular genes encoding for cytokines, major histocompatibility complex (MHC), proteins for antigen presentation, and receptors for neutrophil adhesion and migration.¹⁹ This indicates a positive correlation between NF- κ B and IL-6 (proinflammatory cytokines) with $r=0.097$ and $p=0.05$.

The markers of insulin resistance were markedly raised in cases as compared to controls. The mean serum HOMA-IR level in the study group (cases) was 2.95 ± 0.26 and in the control group was $1.95 \pm 0.29 \mu\text{M}$. The difference between the two was significant ($p=0.012$). The mean serum insulin level in the study group (cases) was 9.96 ± 5.25 and in the control group was $6.85 \pm 4.9 \mu\text{M}$. The difference between the two was significant ($p=0.003$). Ducimetiere²⁰ also showed that Insulin resistance and/or compensatory hyperinsulinemia predict CHD risk in non-diabetic population. In other study by Abbasi et al²¹ in 314 non-diabetic population, it was proposed that insulin resistance at any given degree of obesity accentuates the risk of CHD. Recently, in 2010, Bertolucci et al²² suggested that increased HOMA-IR is positively associated with angiographic coronary artery disease, and may be useful for risk stratification as a high-specificity test for coronary artery disease.

CONCLUSION

Thus, we postulate that atherogenesis is interplay between pro-inflammatory and anti-inflammatory markers. Insulin resistance further predisposes to atherosclerosis due to decreased anti-inflammatory and insulin sensitizing effects of insulin. Our study also highlighted the critical role of the novel marker, NF- κ B which is a mediator of inflammation in etiopathogenesis of atherosclerosis.

So, these findings suggest that inflammation, endothelial dysfunction and insulin resistance interact with each other to promote atherogenesis in an individual predisposed to cardiovascular risk. This indicates that these novel biomarkers of non-invasive diagnosis of atherosclerosis.

These parameters must be further evaluated in larger sample size for their potential as biomarkers of severity of atherosclerosis

REFERENCES

1. Kumar V, Abbas AK, Fausto N, Fausto JC. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier; 2007.p.571-4.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation*. 2001;104:2746–53.
3. Gupta R. Burden of coronary heart disease in India. *Indian Heart J*. 2005;57:632-8.
4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation*. 2002;105:1135–43.
5. C Antoniades C, D Tousoulis D et al. Vascular endothelium and inflammatory process, in patients with combined type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C. *Diabet Med*. 2004;21(6):552–8.
6. J Van Snick J. Interleukin-6: an overview. *Annu Rev Immunol*. 1990;8:253–78.
7. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. *Circulation*. 2000;101:1767–72.
8. M Trovati M, G Anfossi G, F Cavalot F, P Massucco P, E Mularoni E, G Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents: studies in vitro and in vivo. *Diabetes*. 1988;37:780–6.
9. HO Steinberg HO, G Brechtel G, A Johnson A, N Fineberg N, AD Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. *J Clin Invest*. 1994;94:1172–9.
10. AM Kahn AM, JC Allen JC, CL Seidel CL, S Zhang S. Insulin inhibits migration of vascular smooth muscle cells with inducible nitric oxide synthase. *Hypertension*. 2000;35:303–6.
11. PP De Feo PP, MG Gaisano MG, MW Haymond MW. Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. *J Clin Invest*. 1991;88:833–40.
12. HL Pahl HL. Activators and target genes of Rel/NF- κ B transcription factors. *Oncogene*. 1999;18:6853–66.
13. JS Yudkin JS, M Kumari M, SE Humphries SE, V Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? *Atherosclerosis*. 2000;148:209–14.
14. JM Fernandez-Real JM, WRicart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. *Endocr Rev*. 2003;24:278–301.
15. I Ikonomidis I, G Athanassopoulos G, J Lekakis J, K Venetsanou K, M Marinou M, K Stamatelopoulos K et al. Myocardial Ischemia Induces Interleukin-6 and Tissue Factor production in Patients With Coronary Artery Disease: A Dobutamine Stress Echocardiography Study. *Circulation*. 2005;112:3272-9.
16. PP Tak PP, GS Firestein GS. NF- κ B: a key role in inflammatory diseases. *J Clin Invest* 2001;107:7-11.
17. Jian JJ, CH Fang CH, MZ Chen MZ, X Chen X. Activation of Nuclear Factor- κ B and Correlation with Elevated Plasma C-reactive Protein in Patients with Unstable Angina. *Heart, Lung and Circulation*. 2004;13(2):173-8.

18. S Gerondakis S, R Grumont R, I Rourke I, M Grossmann M. The regulation and roles of Rel/NF- κ B transcription factors during lymphocyte activation. *Curr Opin Immunol*. 1998;10:353-9.
19. P Ducimetiere P, E Eschwege E et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. *Diabetologia*. 1980;19:205-10.
20. G Reaven G, F Abbasi F, T McLaughlin T. Obesity, Insulin Resistance, and Cardiovascular Disease. *Recent Progress in Hormone Research* 2004;59:207-23.
21. MC Bertoluci MC, AS Quadros AS et al. Insulin resistance and triglyceride/HDLc index are associated with coronary artery disease. *Diabetology & Metabolic Syndrome*. 2010;2:11.
22. HN Ginsberg HN. New Perspectives on Atherogenesis: Role Of Abnormal Triglyceride-Rich Lipoprotein Metabolism. *Circulation*. 2002;106:2137-42.

Source of Support: Nil.

Conflict of Interest: None Declared.

Copyright: © the author(s) and publisher. IJMRP is an official publication of Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article as: Arpita Suri, Ritu Singh, Sanjay Tyagi, Jayashree Bhattacharjee. Role of IL-6 and Insulin Resistance in the Etiopathogenesis of Atherosclerosis. *Int J Med Res Prof*. 2018 July; 4(4):36-40. DOI:10.21276/ijmrp.2018.4.4.010